US appeals court upholds ruling invalidating Johnson and Johnson patent on Remicade
A U.S. appeals court upheld a ruling that invalidated a crucial Johnson and Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.
The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent.
Remicade generated U.S. sales of $4.8 billion for J&J in 2016 but it faces increased competition from cheaper “biosimilar” copycats, including Pfizer’s version, which is sold in the United States under the name Inflectra.
J&J said at the time that it considered Pfizer’s manoeuvre to be an “at risk” launch, meaning that Pfizer would be liable for money damages to J&J if an appeals court reversed the rulings and upheld the patent.
J&J did not immediately respond to a request for comment on Tuesday’s ruling.
Pfizer praised the ruling but said in a statement that J&J ”continues to use their scheme of exclusionary contracts to maintain Remicade’s monopoly position that prevents patients, payers, and providers from the opportunity to benefit from Inflectra.”
Pfizer sued J&J in September, saying its rival violated U.S. antitrust laws offering insurers discounts on Remicade in exchange for essentially excluding Inflectra from insurance coverage.
J&J has said the lawsuit is without merit and that the company is competing on value and price.
(Reporting by Jan Wolfe; Editing by Bernadette Baum and Frances Kerry)
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd